To validate the DecisionDx 31-gene expression profiling assay for predicting long-term oncologic outcomes in patients with cutaneous melanoma and to identify sub-groups that may benefit from clinical management changes using GEP.
Approach:
Study Design: Retrospective analysis of a prospectively identified cohort of patients with invasive cutaneous melanoma (AJCC clinical stages I–III) referred for 31-GEP testing from 2015 to 2022.
Data Collection: Demographic and clinical data were collected, and primary outcomes included recurrence-free survival (RFS), distant metastasis-free survival (DMFS), and melanoma-specific survival (MSS).
Key Findings:
GEP serves as an independent predictor of survival outcomes after accounting for other relevant clinicopathologic factors.
The study aimed to address limitations in existing literature regarding GEP performance in unselected populations, specifically focusing on recurrence-free survival (RFS), distant metastasis-free survival (DMFS), and melanoma-specific survival (MSS).
Interpretation:
Integration of GEP testing into standard care remains controversial, with calls for more robust, independent data before routine replacement of established staging methods.
Limitations:
Lack of prospective validation in unselected populations.
Potential biases in industry-funded studies that may affect the generalizability of results.
Conclusion:
The study seeks to validate the 31-GEP assay and identify sub-groups for potential clinical management changes.
by Daniel B. Gehle, Philip W. Morgan, Emme M. Fitts, Nathaniel L. Hauser, Chelsea R. Olson, Andrew M. Fleming, Julia Pedo Freitas, Feng Liu-Smith, Simonne S. Nouer, Andrew J. Murphy, Martin D. Fleming
